Publications by authors named "Geoffrey L Uy"

79Publications

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

Blood Adv 2020 Jul;4(13):3180-3190

Center for International Blood and Marrow Transplant Research, Department of Medicine, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362362PMC
July 2020

All I Really Need to Know I Learned From Pediatric Oncologists.

Authors:
Geoffrey L Uy

JCO Oncol Pract 2020 May;16(5):239-240

Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00045DOI Listing
May 2020

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.

Invest New Drugs 2020 Oct 4;38(5):1430-1441. Epub 2020 Feb 4.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00907-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497671PMC
October 2020

Choosing induction chemotherapy in therapy-related acute myeloid leukemia.

Best Pract Res Clin Haematol 2019 03 26;32(1):89-97. Epub 2019 Feb 26.

Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave., CB 8007, Saint Louis, Missouri 63110, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.02.013DOI Listing
March 2019

Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Curr Hematol Malig Rep 2018 12;13(6):417-425

Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave, CB 8007, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0472-8
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0472-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295344PMC
December 2018

Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

N Engl J Med 2018 Sep;379(11):1028-1041

From the Department of Pathology and Immunology (E.J.D.), the Department of Medicine, Division of Oncology (M.A.J., C.A.M., N.E., J.S., K.E., J.R., S.E.H., K.B., L.D.W., M.J.C., I.P., J.S.W., G.L.U., D.C.L., J.F.D., P.W., T.J.L., M.J.W.), the McDonnell Genome Institute (G.S.C., C.A.M., H.A., R.S.F., C.C.F., M.O.), the Department of Medicine, Division of Hospital Medicine (R.S.), and Siteman Biostatistics Shared Resource, Siteman Cancer Center (K.T.), Washington University School of Medicine in St. Louis, St. Louis; and Massachusetts General Hospital Cancer Center, Boston (T.A.G.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804714
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309244PMC
September 2018

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

J Clin Oncol 2018 09 19;36(26):2684-2692. Epub 2018 Jul 19.

Jeffrey E. Lancet, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Geoffrey L. Uy, Washington University School of Medicine, St Louis, MO; Jorge E. Cortes, The University of Texas MD Anderson Cancer Center, Houston, TX; Laura F. Newell, Oregon Health & Science University, Portland, OR; Tara L. Lin, University of Kansas Medical Center, Kansas City, KS; Ellen K. Ritchie, Weill Cornell Medical College, New York; Jonathan E. Kolitz, Northwell Health System, Lake Success; Daniel H. Ryan, University of Rochester, Rochester, NY; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; Stephen A. Strickland, Vanderbilt-Ingram Cancer Center, Nashville, TN; Donna Hogge, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada; Scott R. Solomon, The Leukemia Program at Northside Hospital Cancer Center Institute, Atlanta, GA; Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA; Dale L. Bixby, University of Michigan, Grass Lake, MI; Gary J. Schiller, University of California-Los Angeles, Los Angeles; Matthew J. Wieduwilt, University of California-San Diego, La Jolla; Kamalika Banerjee, Michael Chiarella, Arthur C. Louie, Jazz Pharmaceuticals, Palo Alto; Bruno C. Medeiros, Stanford University School of Medicine, Stanford, CA; and Antje Hoering, Cancer Research and Biostatistics, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127025PMC
September 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.

Transpl Infect Dis 2017 Feb 28;19(1). Epub 2016 Dec 28.

Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tid.12629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459579PMC
February 2017

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

N Engl J Med 2016 11;375(21):2023-2036

the Department of Internal Medicine, Division of Oncology (J.S.W., L.D.W., G.L.U., A.G., M.H.T., I.P., R.R., T.A.F., K.E.S.-G., R.V., S.T.O., C.N.A., A.F.C., M.A.S., M.A.J., S.E.H., K.L., M.R.J., M.J.W., P.W., D.C.L., J.F.D., T.J.L.), and the Division of Biostatistics (J.D.B.), and the Department of Pathology and Immunology (E.J.D., B.T., Y.-S.L.), Washington University School of Medicine, and McDonnell Genome Institute, Washington University in St. Louis (A.A.P., C.A.M., C.C.F., M.O., R.S.F., R.K.W., L.D.W., T.J.L.) - both in St. Louis; the Departments of Internal Medicine (A.H., N.K., M.J.S., W.S.) and Pharmacy (R.W.K.), University of Chicago, Chicago; and the Department of Internal Medicine (T.A.G.), Massachusetts General Hospital, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1605949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217532PMC
November 2016

Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.

Leuk Res 2015 Dec 1;39(12):1437-42. Epub 2015 Oct 1.

Division of Oncology, Washington University School of Medicine, St. Louis, MO, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.09.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661095PMC
December 2015

Targeting the microenvironment in acute myeloid leukemia.

Curr Hematol Malig Rep 2015 Jun;10(2):126-31

Section of BMT & Leukemia, Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave. Campus Box 8007, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0255-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447552PMC
June 2015

Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.

Am J Hematol 2014 May 3;89(5):487-92. Epub 2014 Mar 3.

Department of Medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23663DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378713PMC
May 2014

Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease.

Sci Transl Med 2013 Jun;5(188):188ra74

Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3005452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859344PMC
June 2013

Expression and function of PML-RARA in the hematopoietic progenitor cells of Ctsg-PML-RARA mice.

PLoS One 2012 8;7(10):e46529. Epub 2012 Oct 8.

Section of Stem Cell Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046529PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466302PMC
June 2013

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Biol Blood Marrow Transplant 2011 Nov 3;17(11):1646-52. Epub 2011 May 3.

Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791110019
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2011.04.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166401PMC
November 2011

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Blood 2011 Feb 4;117(6):1828-33. Epub 2010 Nov 4.

Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-07-297143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318598PMC
February 2011

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia.

Blood 2010 Nov 20;116(18):3604-10. Epub 2010 Jul 20.

Section of Stem Cell Biology, Division of Oncology, Washington University School of Medicine, 660 S. Euclid Avenue, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-11-189282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981479PMC
November 2010

Plerixafor.

Nat Rev Drug Discov 2009 Feb;8(2):105-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2819DOI Listing
February 2009

Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

Leuk Lymphoma 2009 Jan;50(1):14-23

Division of Medical Oncology, Department of Medicine, Washington University, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802517765DOI Listing
January 2009

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

Expert Opin Biol Ther 2008 Nov;8(11):1797-804

Washington University School of Medicine, Division of Oncology, 660 S. Euclid Avenue, Campus Box 8007, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.8.11.1797DOI Listing
November 2008

Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

Clin Lymphoma Myeloma 2007 Nov;7(9):587-9

Section of Bone Marrow Transplant and Leukemia, Division of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2007.n.045DOI Listing
November 2007

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.

Haematologica 2006 Nov 17;91(11):1581-2. Epub 2006 Oct 17.

View Article

Download full-text PDF

Source
November 2006